Bio-Rad reported fourth quarter 2025 net sales of $693 million, a 3.9% reported increase (1.7% currency-neutral), driven primarily by an 8.4% jump in Clinical Diagnostics sales. For the full year, sales reached $2.583 billion, up 0.7% reported but essentially flat on a currency-neutral basis. Profitability faced significant pressure, with non-GAAP gross margin falling to 52.5% in Q4 and 53.3% for the full year due to supply chain costs and expedited freight, leading to a full-year non-GAAP EPS of $9.92, down from $10.31 in the prior year. Despite these headwinds, the company generated robust free cash flow of $375 million, a 29% increase year-over-year, aided by working capital efficiency. Looking ahead to 2026, management issued conservative guidance for currency-neutral revenue growth of 0.5% to 1.5%, with gross margin expected to recover to 54% to 54.5% as operational initiatives take hold and the QX700 ddPCR platform gains traction.
| Metric | Value | Change |
|---|---|---|
| Q4 Net Sales | $693 million | +3.9% Reported / +1.7% CN |
| FY 2025 Net Sales | $2.583 billion | +0.7% Reported / Flat CN |
| Q4 Non-GAAP EPS | $2.51 | -13.4% YoY |
| FY 2025 Non-GAAP EPS | $9.92 | -3.8% YoY |
| Q4 Non-GAAP Gross Margin | 52.5% | -140 bps YoY |
| FY 2025 Free Cash Flow | $375 million | +29.3% YoY |
| Q4 Clinical Diagnostics Sales | $425 million | +8.4% Reported / +5.6% CN |
| Q4 Life Science Sales | $268 million | -2.6% Reported / -4.0% CN |
Bio-Rad is prioritizing the expansion of its Digital PCR (ddPCR) franchise as a core long-term growth pillar. Management highlighted 'meaningful acceleration in QX700 instrument sales' during the quarter, driven by both conversions from qPCR and competitive wins. The company believes its broad portfolio positions it to sustain leadership, with the QX700 enabling expansion into the entry-level segment. This focus is supported by the integration of the Stilla acquisition, which is now expected to be accretive by mid-2026, earlier than initially anticipated.
Operational restructuring and cost discipline remain a key strategic focus to combat margin pressure. The company completed a restructuring program in 2025, with savings reflected in the 2026 outlook. Management stated they are 'executing actions to improve operational performance, expand margins and focus investments in our most attractive growth platforms.' This includes a sharpened focus on R&D to reinforce high-value segments, with plans to launch an IVD version of the QX600 and incorporate AI into future platforms in 2026.
The Clinical Diagnostics segment has returned to growth, serving as a stabilizing force for the company. Performance was driven by 'successful fulfillment of large customer orders in our quality control portfolio' and the annualization of reimbursement changes in China. Management projects mid-single-digit growth for quality controls and low single-digit growth for the rest of the diagnostics portfolio, indicating a steady, albeit modest, recovery trajectory for this segment.
Bio-Rad is actively deploying capital towards M&A and share repurchases to enhance shareholder value. Following the 'measured scale' of the Stilla acquisition, the company continues to look for 'additional assets to help accelerate the top line.' While buybacks were paused in Q4, the company retired 1.2 million shares in 2025 and retains approximately $285 million under its current authorization, signaling a commitment to capital allocation despite near-term operational pauses.
Significant operational execution failures led to a gross margin shortfall of 140 basis points in Q4 (non-GAAP) compared to the prior year. Management admitted that 'gross margin did not meet our expectations,' citing 'execution-related rather than structural' issues. Specifically, an extended U.S. government shutdown forced the company to compress three months of work into one month, resulting in 'higher expenses for expedited freight and service costs.' This raises concerns about supply chain resilience and planning capabilities.
The Process Chromatography business is facing a severe contraction, projected to decline by 'mid-teens' in 2026. This decline is driven by changes in government regulations regarding vaccine usage and improved customer production efficiencies. Management noted that this business contributes to 'revenue concentration from a select number of commercial therapeutics,' highlighting a concentration risk that is currently materializing negatively and impacting the overall growth profile.
Guidance for 2026 implies very muted top-line growth, with currency-neutral revenue expected to increase only 0.5% to 1.5%. Even excluding the struggling Process Chromatography segment, core Life Science growth is anticipated at only 4%. This conservative outlook suggests that management does not foresee a immediate robust recovery in end markets like academia or biopharma funding, keeping the company in a low-growth mode for the near future.
Free cash flow conversion, while strong at 138% of non-GAAP net income, was aided by working capital efficiency rather than pure earnings growth. With operating income declining year-over-year in Q4 and flat for the full year, the sustainability of high FCF conversion rates may be pressured if inventory management normalizes or if the company needs to ramp up spending to fix the operational issues identified in the supply chain.
Overall: Management displayed a tone of accountability regarding operational missteps, particularly concerning gross margin shortfalls, while maintaining confidence in the company's long-term strategic pillars and product portfolio. They were transparent about the specific causes of recent failures, such as supply chain execution, and shifted to a pragmatic, cautious stance when discussing 2026 guidance, emphasizing realism over optimism.
Confidence: MEDIUM - Management acknowledged significant execution failures ('gross margin did not meet our expectations') and provided conservative guidance for 2026. While they expressed confidence in new products like QX700 and the Stilla acquisition, the reliance on 'early signs of stabilization' and the need for 'operational rigor' suggests a transition period before full confidence is restored.
0.5% to 1.5% Currency-Neutral
54.0% to 54.5% Non-GAAP
12.0% to 12.5% Non-GAAP
$375 million to $395 million
~4%
~Mid-teens decline
Hedging & Uncertainty: Management frequently used qualifiers to temper expectations regarding the timing and magnitude of a recovery. Phrases like 'appropriately cautious,' 'trying to be very realistic,' and 'early signs of stabilization' suggest a reluctance to commit to a strong near-term rebound. When discussing the Process Chromatography headwinds, they used conditional language, stating recovery depends on how customers 'move through clinical phases,' effectively pushing out the timeline for investor expectations. The admission that gross margin issues were 'execution-related rather than structural' serves as a hedge to reassure investors that the core business model remains sound despite current poor performance.
Gross margin did not meet our expectations or frankly, what Bio-Rad is capable of delivering. - Jonathan DiVincenzo, President and COO
We effectively had to do 90 days of work in 30 days to support our customers. - Roop Lakkaraju, Executive Vice President and CFO
We're trying to be very realistic. - Roop Lakkaraju, Executive Vice President and CFO
We remain appropriately cautious and continue to closely monitor policy development. - Jonathan DiVincenzo, President and COO
We believe these early trends set an encouraging tone for 2026. - Norman Schwartz, Chief Executive Officer
We are guiding currency-neutral revenue growth for the full year to be between 0.5% and 1.5%. - Roop Lakkaraju, Executive Vice President and CFO
Analyst Sentiment: Analysts expressed skepticism regarding the conservative nature of the 2026 guidance, particularly the operating margin outlook and the lack of buyback activity in Q4 despite strong cash flow. There was persistent probing into the Process Chromatography decline, with analysts asking 'three ways' to understand the severity and duration of the headwind.
Management Responses: Management remained defensive but detailed regarding the Process Chromatography issues, citing specific regulatory changes and customer strategies. They justified the conservative margin guide by pointing to the 50-basis-point headwind from Process Chromatography and the need for 'realism' regarding the pace of recovery. They dismissed the lack of buybacks as a timing issue rather than a strategic signal.
Analysts pressed for details on the 'mid-teens decline' in Process Chromatography, seeking to understand if the issue was structural or customer-specific. Management clarified it was due to vaccine demand changes and customer efficiency gains, expecting a return to low-single-digit growth by 2027.
The conservatism of the 2026 operating margin guide (12-12.5%) was questioned, given the completion of restructuring. Management explained that the savings are already in the guide but are being offset by the mix shift from lower-margin Process Chromatography sales.
The lack of share repurchases in Q4 was queried. Management stated they are being 'opportunistic' and looking at M&A, but the pause should not be viewed as a leading indicator.
Bio-Rad is currently navigating a complex transition period characterized by operational execution failures and a significant, though temporary, demand shock in its Process Chromatography business. While the company boasts strong long-term growth drivers in its Digital PCR (QX700) and Quality Control portfolios, and generates impressive free cash flow ($375M), the near-term outlook is clouded by gross margin pressure and muted revenue growth guidance (0.5-1.5%). The admission of supply chain failures—having to 'do 90 days of work in 30 days'—raises concerns about management's operational control. Until the company demonstrates a consistent recovery in gross margins towards the 54% target and stabilizes the Life Science segment, the stock is likely to remain range-bound, warranting a Hold rating until execution improves.
The extended U.S. government shutdown caused operational disruptions, forcing Bio-Rad to incur expedited freight costs to meet customer demand, compressing quarterly timelines and negatively impacting margins.
Management noted improved funding conditions in the second half of 2025, skewed towards later-stage biotech companies, which supports a modest recovery expectation for the core Life Science portfolio in 2026.
Cautious spending persists in academia and government; institutions are prioritizing staffing and sustaining ongoing research over purchasing capital equipment, dampening instrument demand.
While annualizing negative reimbursement changes in China provides a tailwind, management remains 'appropriately cautious' about potential future VBP (Volume-Based Procurement) headwinds.